Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib dose-ranging randomized phase 2 trial in resistant chronic phase chronic myeloid leukemia
NL-OMON43934Phase 2Withdrawn
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ponatinib in chronic myelogenous leukemia (CML) (3 arms), sponsored by ARIAD Pharmaceuticals, Inc. Primary endpoint: Major cytogenetic response by 12 months. Planned start Sep 2015; status: withdrawn.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON43934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43934.